Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).

Annika Kurreck,Michael Geissler,Uwe M. Martens,Jorge Riera-Knorrenschild,Jobst Greeve,Axel Florschütz,Swen Wessendorf,Thomas Jens Ettrich,Stephan Kanzler,Nörenberg Dominik,Max Seidensticker,Swantje Held,Petra Buechner-Steudel,Jens Atzpodien,Volker Heinemann,Sebastian Stintzing,Thomas Seufferlein,Andrea Tannapfel,Anke Reinacher,Dominik Paul Modest

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).

2020

e16055Background: In patients with mCRC, dynamics of response and disease progression may play a critical role in the understanding of long-term outcome. Depth of response (DpR), time to DpR and po...

Keywords:

Oncology
Colorectal cancer
treatment response
FOLFOXIRI
disease progression
Pathology
Internal medicine
Medicine
Panitumumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations